Visfatin as a Biomarker of Obesity in Iraqi Adolescences with Metabolic Syndrome

Abstract

The present work aims to study the relationship betweenvisfatin levels and metabolic syndrome in Iraqi obese adolescence (with and without metabolic syndrome) and its relation with other studied biochemical parameters. Sixty obese adolescence were depended in this study (with and without metabolic syndrome), compared with (30) non-obese children as control. This study was done in the period from April 2020 until the end of December 2020, in the National Diabetes Center/Mustansiriya University, Baghdad/Iraq. No significant difference in age, height, waist circumferences, and diastolic blood pressure in the patients' groups. In contrast, a significant increase differs (p < 0.05) was recorded in the values of both weights, body mass index, systolic blood pressure, and fasting blood sugar in the adolescent group with metabolic syndrome compared with the adolescent group without metabolic syndrome. Results: The study results showed a highly significant increase difference (P<0.001) in clinical levels of insulin, homo stasis assessment insulin resistance, triglyceride, high density lipoprotein, and visfatin in patientsgroups when comparedwith control. Conclusions:The prevalence of metabolic syndrome between adolescence in developing countries is rising, and this is largely driven by increasing obesity rates.Elevated serum visfatin level in adolescence with metabolic syndrome when compared without metabolic syndromeand a positive correlation between visfatin level with metabolic syndrome factors in adolescence,therefore, visfatin may be considered a risk indicator for heart diseasesand diabetes in these individuals in old age.